Wall Street analysts expect that Ovid Therapeutics Inc (NASDAQ:OVID) will announce earnings per share of ($0.38) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Ovid Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.35) and the lowest estimate coming in at ($0.40). Ovid Therapeutics reported earnings of ($0.53) per share during the same quarter last year, which indicates a positive year over year growth rate of 28.3%. The firm is expected to issue its next quarterly earnings results on Thursday, November 14th.
On average, analysts expect that Ovid Therapeutics will report full year earnings of ($1.53) per share for the current fiscal year, with EPS estimates ranging from ($1.66) to ($1.37). For the next financial year, analysts forecast that the business will report earnings of ($2.02) per share, with EPS estimates ranging from ($3.64) to ($0.65). Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that that provide coverage for Ovid Therapeutics.
Ovid Therapeutics (NASDAQ:OVID) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.08.
NASDAQ OVID traded down $0.13 during trading on Friday, reaching $1.91. 58,565 shares of the company traded hands, compared to its average volume of 107,033. The company has a quick ratio of 5.84, a current ratio of 5.84 and a debt-to-equity ratio of 0.01. The stock’s 50 day moving average price is $2.21 and its two-hundred day moving average price is $1.99. Ovid Therapeutics has a 1-year low of $1.53 and a 1-year high of $6.83.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its holdings in Ovid Therapeutics by 67.8% during the second quarter. Vanguard Group Inc. now owns 1,097,614 shares of the company’s stock valued at $2,030,000 after purchasing an additional 443,490 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in shares of Ovid Therapeutics by 29.8% in the 2nd quarter. Renaissance Technologies LLC now owns 471,609 shares of the company’s stock worth $872,000 after acquiring an additional 108,392 shares in the last quarter. Wells Fargo & Company MN boosted its holdings in shares of Ovid Therapeutics by 41.0% in the 2nd quarter. Wells Fargo & Company MN now owns 442,604 shares of the company’s stock worth $819,000 after acquiring an additional 128,618 shares in the last quarter. Acadian Asset Management LLC boosted its holdings in shares of Ovid Therapeutics by 37.4% in the 2nd quarter. Acadian Asset Management LLC now owns 211,490 shares of the company’s stock worth $392,000 after acquiring an additional 57,592 shares in the last quarter. Finally, Geode Capital Management LLC boosted its holdings in shares of Ovid Therapeutics by 7.1% in the 4th quarter. Geode Capital Management LLC now owns 95,865 shares of the company’s stock worth $231,000 after acquiring an additional 6,391 shares in the last quarter. 30.77% of the stock is currently owned by institutional investors.
Ovid Therapeutics Company Profile
Ovid Therapeutics Inc, a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which has completed Phase II clinical trial for adults with angelman syndrome; and Phase I clinical trial for adolescents with angelman syndrome or fragile X syndrome.
Featured Article: What is the Stochastic Momentum Index (SMI)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ovid Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ovid Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.